With rare exceptions, all studies be reported that way, IMO.
The narrative portion of MRK's PR has the details needed to construct the SVR12 data on an ITT basis, but investors shouldn't have to do the extra compilation work to get it.
the number of patients who dropped off protocol seems high. it's a small study, but still tends to make me wonder about tolerability/SEs I seem to recall their PI wasn't the cleanest in dose ranging studies (I could be totally wrong here), but now I can't help but wonder
Market Data 
Markets 
AI
